N/A
N=57
Insulin-sensitive Obesity: Lessons From Longitudinal Data
Insulin Sensitivity/Resistance · Obesity
Bottom Line
View on ClinicalTrials.gov: NCT02017210 ↗Enrolled (actual)
57
Serious AEs
—
Results posted
Feb 2020
Primary outcome: Primary: Insulin Sensitivity — 0.0105; -0.0076; 0.0041 micro mol/min/Kg/mU/L/year
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 26+ yrs
- Sex
- All
- Sponsor
- Garvan Institute of Medical Research
- Primary completion
- Feb 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Insulin Sensitivity |
0.0105; -0.0076; 0.0041 | — |
| SECONDARY Body Mass Index |
0.0526; 0.0941; 0.0088 | — |
| SECONDARY Waist Circumference |
0.5263; 0.4894; 0.0000 | — |
| SECONDARY Body Fat Mass |
0.2281; 0.3696; 0.3478 | — |
| SECONDARY Body FFM |
-0.0382; -0.1786; -0.4017 | — |
| SECONDARY Visceral Fat Volume |
13.3962; 47.3351; 46.2974 | — |
| SECONDARY Systolic Blood Pressure |
0.3704; 0.9483; 1.3593 | — |
| SECONDARY Diastolic Blood Pressure |
1.1290; 0.4117; 0.5662 | — |
| SECONDARY Fasting Blood Glucose |
-0.0151; 0.0062; -0.0254 | — |
| SECONDARY Fasting Serum Insulin |
0.2223; 0.0855; -0.2370 | — |
Summary
People who are overweight and/or obese are at risk of insulin resistance and type 2 diabetes. However, research has shown that some overweight and/or obese individuals remain insulin-sensitive and metabolically healthy despite their unhealthy body weight.
The investigators hypothesise that overweight and/or obese people who were deemed insulin-sensitive in previous studies will maintain their insulin sensitivity and metabolic health over time. The investigators also hypothesise that the preservation of insulin sensitivity will be accompanied by key metabolic health markers.
Eligibility Criteria
Inclusion Criteria
- Participation in two previous studies conducted at the Garvan Institute of Medical Research Clinical Research Facility (described in the other publications 1-3).
- Willingness to give written informed consent and willingness to participate in the study.
Exclusion Criteria
- Pregnant and/or lactating women.
Data sourced from ClinicalTrials.gov (NCT02017210). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.